Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat
In a preliminary uncontrolled study of 21 veterans with traumatic brain injury, participation in two psilocybin retreat ceremonies was associated with large reductions in PTSD, depression and anxiety symptoms and with EEG changes (reduced frontal/temporal delta–theta power and increased alpha–beta coherence) consistent with improved emotional regulation and neural communication. These findings suggest psilocybin retreats may improve psychological wellbeing and brain connectivity in veterans with TBI and warrant larger, controlled trials.
Authors
- Robin Carhart-Harris
- Leor Roseman
- David Erritzoe
Published
Abstract
Introduction
Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological symptoms such as post-traumatic stress disorder (PTSD) and depression. This study investigates the effects of psilocybin administered in retreat settings on veterans with a history of TBI, focusing on mental health outcomes and changes in brain connectivity as measured by EEG.
Methods
A total of 21 participants were recruited through the Heroic Hearts Project, which facilitated access to two six-day psilocybin retreats in Jamaica. Before the retreat, participants underwent three individual and three group coaching sessions to prepare for the experience. During the retreat, two psilocybin ceremonies were held, spaced 48 hours apart. Participants received an initial dose of 1.5g to 3.5g of dried psilocybin mushrooms, with the option to increase the second dose up to 5g. Psilocybin was administered in a tea format, under the supervision of experienced facilitators. Psychological outcomes were assessed using validated questionnaires (PCL-5, PHQ-9, STAI) at baseline (four weeks pre-retreat) and four weeks post-retreat. Electroencephalography (EEG) was used to measure brainwave activity pre- and post-treatment. Paired t-tests were used to analyze changes in psychological scores, while EEG frequency band analysis assessed changes in brain function and connectivity.
Results
Improvements were observed across several mental health measures: PTSD (PCL-5 scores decreased by 50%, p=0.010), depression (PHQ-9 scores decreased by 65%, p<0.001), and anxiety (STAI) scores decreased by 28%, p<0.001). EEG data showed decreased delta and theta power in frontal and temporal regions, indicating potential improvements in cognitive control and emotional processing. Enhanced coherence in alpha and beta bands suggested improved neural communication.
Discussion
The study suggests that psilocybin retreats might provide improvements in psychological well-being and brain connectivity in veterans with TBI. Reduced delta power and normalised theta activity suggest better emotional regulation, while improved coherence in alpha and beta bands may reflect increased cognitive engagement. Further, these preliminary outcomes provide a potential rationale for the design and implementation of larger-scale, controlled studies to validate and expand upon these initial findings.
Research Summary of 'Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat'
Introduction
Psilocybin is a serotonergic psychedelic that acts mainly at 5-HT2A receptors and has been proposed to promote neuroplasticity and to reorganise functional connectivity in networks supporting emotion and cognition. Veterans are at elevated risk of traumatic brain injury (TBI) and commonly experience chronic neurological and psychiatric sequelae such as depression, anxiety and post-traumatic stress disorder (PTSD). Electroencephalography (EEG) studies of TBI have repeatedly documented persistent abnormalities in spectral power and coherence, most notably elevated slow-wave activity in delta and theta bands and attenuated alpha and beta rhythms, which are thought to reflect disrupted thalamocortical and cortical network function. Blest-Hopley and colleagues set out to evaluate whether participation in residential psilocybin retreats was associated with improvements in mental health and concomitant changes in resting-state EEG among veterans reporting prior TBI. The authors hypothesised that retreat attendance would reduce delta power and normalise theta activity, while increasing alpha and beta power and coherence, with effects localising primarily to frontal and temporal regions. Psychological outcomes were to be measured with validated questionnaires and neurofunctional changes assessed using pre- and post-retreat EEG recordings collected at the retreat site.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Blest-Hopley, G., Pasculli, G., Ruffell, S. G. D., Tsang, W., Emmanuel, O., Pate, K. M., Kettner, H., Roseman, L., Erritzoe, D., & Carhart-Harris, R. (2025). Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat. Frontiers in Psychiatry, 16. https://doi.org/10.3389/fpsyt.2025.1594307
References (23)
Papers cited by this study that are also in Blossom
Vargas, A. S., Luís, Â., Barroso, M. et al. · Biomedicines (2020)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Khan, S. I., Carter, G. T., Aggarwal, S. K. et al. · Frontiers in Neuroscience (2021)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Nichols, D. E. · Pharmacological Reviews (2016)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Dos Santos, R. G., Bouso, J. C., Hallak, J. E. · Expert Review of Clinical Pharmacology (2018)
Show all 23 referencesShow fewer
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
MacCallum, C. A., Pistawka, C. A., Deol, J. K. et al. · Frontiers in Psychiatry (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)
Davis, A. K., Streeter Barrett, F., Cosimano, M. P. et al. · Journal of Psychopharmacology (2022)
Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)
Weiss, B., Dinh-Williams, L. A. L., Beller, N. et al. · Psychological Trauma (2024)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Smedfors, G., Glotfelty, E., Papatziamos, C. et al. · Research Square (2022)
Kozłowska, U., Klimczak, A., Wiatr, K. et al. · Biorxiv (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.